Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction.

Flores, M Luz; Castilla, Carolina; Ávila, Rainiero; Ruiz-Borrego, Manuel; Sáez, Carmen; Japón, Miguel A

Flores, M Luz; Castilla, Carolina; Ávila, Rainiero; Ruiz-Borrego, Manuel; Sáez, Carmen; Japón, Miguel A.

Affiliation

Flores ML; Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Avenida Manuel Siurot s/n, Seville 41013, Spain.

Breast Cancer Res Treat ; 133(3): 917-28, 2012 Jun.

Article in En | MEDLINE | ID: mdl-22076480

Subject(s)

Antineoplastic Agents, Phytogenic/pharmacology; Breast Neoplasms/metabolism; M Phase Cell Cycle Checkpoints/drug effects; Paclitaxel/pharmacology; bcl-2 Homologous Antagonist-Killer Protein/metabolism; bcl-X Protein/metabolism; Antineoplastic Agents, Phytogenic/therapeutic use; Apoptosis/drug effects; Apoptosis/genetics; Breast Neoplasms/drug therapy; Breast Neoplasms/mortality; Cell Line, Tumor; Female; Humans; Isothiocyanates/pharmacology; Paclitaxel/therapeutic use; Protein Binding

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Paclitaxel / Bcl-2 Homologous Antagonist-Killer Protein / Bcl-X Protein / M Phase Cell Cycle Checkpoints / Antineoplastic Agents, Phytogenic Type of study: Diagnostic_studies Limits: Female / Humans Language: En Journal: Breast Cancer Res Treat Year: 2012 Document type: Article Affiliation country: Spain

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google